拜瑪林製藥 BMRN 深 滬
等待開盤 06-26 09:30:00 美东时间
57.29
-0.040
-0.07%
華盛通- 最 高57.9499
- 今 開57.46
- 成交量 96.59万股
- 最 低 56.40
- 昨 收 57.33
- 總市值 110.73亿
- 52周最高 66.275
- 市盈率 靜 31.74
- 換手率 0.50%
- 52周最低 49.2592
- 委 比 55.77%
- 總股本 1.93亿
- 歷史最高 151.75
- 量 比 0.42
- 振 幅 2.70%
- 歷史最低 23.735
- 每 手 1
- 風險率 2.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation Score
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were presented at ENDO 2026, the Endocrine Society Annual Meeting, in Chicago. New data from a Phase 2, in...
06-16 21:13
拜玛林制药完成48亿美元收购 一季度业绩超预期上调全年指引
经济观察网 拜玛林制药近期完成对Amicus Therapeutics收购，一季度业绩超预期，上调全年营收指引。 战略推进： 公司于2026年4月27日宣布完成...
05-29 05:36
BioMarin Reveals Dwarfism Study Data, Stock Soars
BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children with hypochondroplasia.
05-22 02:11
BioMarin gains on Voxzogo phase 3 results
BioMarin Pharmaceutical (BMRN) is up ~3% in after-hours trading Wednesday after posting phase 3 data for Voxzogo (vosoritide) in children with hypochondroplasia that met its primary endpoint. Children...
05-21 06:09
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
BioMarin Pharmaceutical Announces Results From Phase 3 Study Of BMN 401 In Children Ages 1-12 With ENPP1 Deficiency; Study Meets Only One Co-Primary Endpoint, Shows No Improvement In Tracked Treatment Impact Scores
ENERGY 3 is a Phase 3 multicenter randomized (2:1) controlled open-label clinical trial designed to evaluate the efficacy and safety of BMN 401 in children ages 1-12 with ENPP1 deficiency. Change from baseline in PPi
05-18 21:10
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Goldman Sachs Reinstates Neutral on BioMarin Pharmaceutical, Announces $69 Price Target
Goldman Sachs analyst Salveen Richter reinstates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and announces $69 price target.
05-11 18:41
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
